Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, announced today that a new independent study demonstrating the clinical accuracy of Masimo noninvasive and continuous hemoglobin (SpHb) monitoring was presented this week at the European Society of Anaesthesiology (ESA) Annual Congress in Helsinki, Finland.
In the study, titled "Comparison Between a New Noninvasive Continuous Technology of Spectrophotometry-based and RBC Count for Haemoglobin Monitoring During Surgery with Hemorrhagic Risk," Dr. Lionel Lamhaut and researchers from the Department of Anesthesiology and Intensive Care at Necker University Hospital in Paris, France, compared the accuracy of Masimo SpHb with hemoglobin measurements obtained invasively via laboratory blood analysis in 20 patients undergoing high blood-loss surgery. SpHb and invasive hemoglobin measurements were simultaneously recorded at the beginning and end of any clinical intervention and before and after blood transfusion. Results showed a strong agreement between the two (0.88), with a bias of 0.26 g/dL and standard deviation of 1.1 g/dL—leading researchers to conclude that this study, conducted under real-world clinical conditions, "confirms the first tests realized by the manufacturer." Affirming the clinical accuracy and utility of Masimo SpHb, researchers further noted that "the correlation is good, suggesting the possibility of a daily use of this technology."
Masimo SpHb is available as part of Masimo Rainbow platform—the first-and-only platform to noninvasively and continuously measure total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®),and acoustic respiration rate (RRa™), in addition to the 'gold standard' Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI).
Overcoming challenges in noninvasive diabetes management through wearable devices